Glutaric acidemia type I
Ultimo aggiornamento 18 Ago 2020
Rispetta le linee guida editoriali
- ScaricaScarica
- Condividi
- Language
- Discussione
- Ask Patient
- Versione audio
- Aggiungi alle fonti preferite su Google
Glutaric acidemia type I (also called glutaric aciduria type I) is an inherited disorder in which the body is unable to process certain proteins properly. It is classified as an organic acid disorder, which is a condition that leads to an abnormal buildup of particular acids known as organic acids. Abnormal levels of organic acids in the blood (organic acidemia), urine (organic aciduria), and tissues can be toxic and can cause serious health problems.
Scelte video per Condizioni geneticheVideo library
Descrizione
Glutaric acidemia type I (also called glutaric aciduria type I) is an inherited disorder in which the body is unable to process certain proteins properly. It is classified as an organic acid disorder, which is a condition that leads to an abnormal buildup of particular acids known as organic acids. Abnormal levels of organic acids in the blood (organic acidemia), urine (organic aciduria), and tissues can be toxic and can cause serious health problems.
People with glutaric acidemia type I have inadequate levels of an enzyme that helps break down the amino acids lysine, hydroxylysine, and tryptophan, which are building blocks of protein. Excessive levels of these amino acids and their intermediate breakdown products can accumulate and cause damage to the brain, particularly the basal ganglia, which are regions that help control movement. Intellectual disability may also occur.
The severity of glutaric acidemia type I varies widely; some individuals are only mildly affected, while others have severe problems. In most cases, signs and symptoms first occur in infancy or early childhood, but in a small number of affected individuals, the disorder first becomes apparent in adolescence or adulthood.
Some babies with glutaric acidemia type I are born with unusually large heads (macrocephaly). Affected individuals may have difficulty moving and may experience spasms, jerking, rigidity, or decreased muscle tone. Some individuals with glutaric acidemia have developed bleeding in the brain or eyes that could be mistaken for the effects of child abuse. Strict dietary control may help limit progression of the neurological damage. Stress caused by infection, fever or other demands on the body may lead to worsening of the signs and symptoms, with only partial recovery.
Modelli di ereditarietà
The source lists the following possible inheritance patterns: Autosomal recessive. More than one pattern can apply in different cases.
Related genes
Altri nomi
GA I
Glutaric acidemia I
Glutaric acidemia type 1
Glutaric aciduria I
Glutaryl-CoA dehydrogenase deficiency
Related patient information and medicines

Patient information leaflet
Test del sangue del neonato
When peopl... Also, a sudden and severe drop in blood sugar levels can occur. All four devolved nations of the United Kingdom now offer screening for four other serious, ma treatable, inherited metabolic diseases. These are: Homocystinuria (HCU). Maple syrup urine disease (MSUD). Aciduria glutarica tipo 1 (GA1). Acidemia isovalerica (IVA). If you.

Patient information leaflet
Diabete nei bambini
Diabetes is a lifelong condition that sometimes starts in childhood. As a result of ongoing research, our understanding of diabetes has greatly improved and there are now extensive support and treatments available for diabetes. About 9 in 10 bambini and young people in the UK who have diabete will have type 1 diabetes, e 1 in 10 will have type.

Patient information leaflet
Diabete di tipo 1
Tipo 1 diabete is the type di diabetes that typically develops in children and in young adults. In type 1 diabetes the body stops making insulin and the blood sugar (glucose) level goes very high. Treatment to control the blood glucose level is with insulin injections and a healthy diet. They include reducing blood pressure if it is high and.

Patient information leaflet
Insulina
Insulina is a hormone made naturally in the body by the pancreas. This hormone controls the level of sugar (glucose) in the blood. For more information on insulin, go to [/health/type-1-diabetes/insulins](https://patient.info/health/type-1-diabetes/insulins) Insulina is a hormone that is made by cells called beta cells. There are.

Patient information leaflet
Trattamento del diabete di tipo 2
If a high zucchero nel sangue level is brought down to a normal level, your symptoms will ease and your risk of long-... GLP-1 (glucagon-like peptide-1) mimetics - exenatide, dulaglutide, liraglutide, lixisenatide and semaglutide Exenatide Exenatide for diabetes , dulaglutide, lixisenatide Lixisenatide for diabetes , liraglutide Liraglutide for diabetes ,.

Patient information leaflet
Malattia renale diabetica
Around one in five people needing dialysis have... Note : most people with diabetes do not need dialysis. For people with type 1 diabetes Roughly 1 in 10 people with diabetes have type 1 diabetes. Type 1 diabetes is an autoimmune condition where the body's immune system destroys the cells that make insulin. It usually begins in childhood or.
Ulteriori letture e riferimenti
- Glutaric acidemia type I; MedlinePlus, National Library of Medicine.
- Basinger AA, Booker JK, Frazier DM, Koeberl DD, Sullivan JA, Muenzer J. Glutaric acidemia type 1 in patients of Lumbee heritage from North Carolina. Mol Genet Metab. 2006 May;88(1):90-2. doi: 10.1016/j.ymgme.2005.12.008. Epub 2006 Feb 8.
- Boy N, Mengler K, Thimm E, Schiergens KA, Marquardt T, Weinhold N, Marquardt I, Das AM, Freisinger P, Grunert SC, Vossbeck J, Steinfeld R, Baumgartner MR, Beblo S, Dieckmann A, Nake A, Lindner M, Heringer J, Hoffmann GF, Muhlhausen C, Maier EM, Ensenauer R, Garbade SF, Kolker S. Newborn screening: A disease-changing intervention for glutaric aciduria type 1. Ann Neurol. 2018 May;83(5):970-979. doi: 10.1002/ana.25233. Epub 2018 Apr 30.
- Boy N, Muhlhausen C, Maier EM, Heringer J, Assmann B, Burgard P, Dixon M, Fleissner S, Greenberg CR, Harting I, Hoffmann GF, Karall D, Koeller DM, Krawinkel MB, Okun JG, Opladen T, Posset R, Sahm K, Zschocke J, Kolker S; Additional individual contributors. Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision. J Inherit Metab Dis. 2017 Jan;40(1):75-101. doi: 10.1007/s10545-016-9999-9. Epub 2016 Nov 16.
- Gerstner B, Gratopp A, Marcinkowski M, Sifringer M, Obladen M, Buhrer C. Glutaric acid and its metabolites cause apoptosis in immature oligodendrocytes: a novel mechanism of white matter degeneration in glutaryl-CoA dehydrogenase deficiency. Pediatr Res. 2005 Jun;57(6):771-6. doi: 10.1203/01.PDR.0000157727.21503.8D. Epub 2005 Mar 17.
- Guerreiro G, Faverzani J, Jacques CED, Marchetti DP, Sitta A, de Moura Coelho D, Kayser A, Kok F, Athayde L, Manfredini V, Wajner M, Vargas CR. Oxidative damage in glutaric aciduria type I patients and the protective effects of l-carnitine treatment. J Cell Biochem. 2018 Dec;119(12):10021-10032. doi: 10.1002/jcb.27332. Epub 2018 Aug 20.
- Hedlund GL, Longo N, Pasquali M. Glutaric acidemia type 1. Am J Med Genet C Semin Med Genet. 2006 May 15;142C(2):86-94. doi: 10.1002/ajmg.c.30088.
- Kolker S, Boy SP, Heringer J, Muller E, Maier EM, Ensenauer R, Muhlhausen C, Schlune A, Greenberg CR, Koeller DM, Hoffmann GF, Haege G, Burgard P. Complementary dietary treatment using lysine-free, arginine-fortified amino acid supplements in glutaric aciduria type I - A decade of experience. Mol Genet Metab. 2012 Sep;107(1-2):72-80. doi: 10.1016/j.ymgme.2012.03.021. Epub 2012 Apr 4.
- Kolker S, Garbade SF, Greenberg CR, Leonard JV, Saudubray JM, Ribes A, Kalkanoglu HS, Lund AM, Merinero B, Wajner M, Troncoso M, Williams M, Walter JH, Campistol J, Marti-Herrero M, Caswill M, Burlina AB, Lagler F, Maier EM, Schwahn B, Tokatli A, Dursun A, Coskun T, Chalmers RA, Koeller DM, Zschocke J, Christensen E, Burgard P, Hoffmann GF. Natural history, outcome, and treatment efficacy in children and adults with glutaryl-CoA dehydrogenase deficiency. Pediatr Res. 2006 Jun;59(6):840-7. doi: 10.1203/01.pdr.0000219387.79887.86. Epub 2006 Apr 26.
- Kolker S, Greenberg CR, Lindner M, Muller E, Naughten ER, Hoffmann GF. Emergency treatment in glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis. 2004;27(6):893-902. doi: 10.1023/B:BOLI.0000045774.51260.ea.
- Kolker S, Koeller DM, Okun JG, Hoffmann GF. Pathomechanisms of neurodegeneration in glutaryl-CoA dehydrogenase deficiency. Ann Neurol. 2004 Jan;55(1):7-12. doi: 10.1002/ana.10784.
- Kulkens S, Harting I, Sauer S, Zschocke J, Hoffmann GF, Gruber S, Bodamer OA, Kolker S. Late-onset neurologic disease in glutaryl-CoA dehydrogenase deficiency. Neurology. 2005 Jun 28;64(12):2142-4. doi: 10.1212/01.WNL.0000167428.12417.B2.
- Lehnert W, Sass JO. Glutaconyl-CoA is the main toxic agent in glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I). Med Hypotheses. 2005;65(2):330-3. doi: 10.1016/j.mehy.2005.02.021.
- Lindner M, Kolker S, Schulze A, Christensen E, Greenberg CR, Hoffmann GF. Neonatal screening for glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis. 2004;27(6):851-9. doi: 10.1023/B:BOLI.0000045769.96657.af.
- Pokora P, Jezela-Stanek A, Rozdzynska-Swiatkowska A, Jurkiewicz E, Bogdanska A, Szymanska E, Rokicki D, Ciara E, Rydzanicz M, Stawinski P, Ploski R, Tylki-Szymanska A. Mild phenotype of glutaric aciduria type 1 in polish patients - novel data from a group of 13 cases. Metab Brain Dis. 2019 Apr;34(2):641-649. doi: 10.1007/s11011-018-0357-5. Epub 2018 Dec 20.
- Screening, Technology and Research in Genetics
- Shadmehri AA, Fattahi N, Pourreza MR, Koohiyan M, Zarifi S, Darbouy M, Sharifi R, Tavakkoly Bazzaz J, Tabatabaiefar MA. Molecular genetic study of glutaric aciduria, type I: Identification of a novel mutation. J Cell Biochem. 2019 Mar;120(3):3367-3372. doi: 10.1002/jcb.27607. Epub 2018 Sep 11.
- Strauss KA, Brumbaugh J, Duffy A, Wardley B, Robinson D, Hendrickson C, Tortorelli S, Moser AB, Puffenberger EG, Rider NL, Morton DH. Safety, efficacy and physiological actions of a lysine-free, arginine-rich formula to treat glutaryl-CoA dehydrogenase deficiency: focus on cerebral amino acid influx. Mol Genet Metab. 2011 Sep-Oct;104(1-2):93-106. doi: 10.1016/j.ymgme.2011.07.003. Epub 2011 Jul 12.
- Strauss KA, Puffenberger EG, Robinson DL, Morton DH. Type I glutaric aciduria, part 1: natural history of 77 patients. Am J Med Genet C Semin Med Genet. 2003 Aug 15;121C(1):38-52. doi: 10.1002/ajmg.c.20007.
- Wajner M, Kolker S, Souza DO, Hoffmann GF, de Mello CF. Modulation of glutamatergic and GABAergic neurotransmission in glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis. 2004;27(6):825-8. doi: 10.1023/B:BOLI.0000045765.37043.fb.
Condividi i tuoi pensieri o esperienze con gli altri nel nostro comunità di pazienti.
Iscriviti alla newsletter di Patient
La tua dose settimanale di consigli sulla salute chiari e affidabili - scritti per aiutarti a sentirti informato, sicuro e in controllo.
Abbonandoti accetti i nostri Informativa sulla Privacy. Puoi annullare l'iscrizione in qualsiasi momento. Non vendiamo mai i tuoi dati.

